Cilostazol improves long-term outcomes after coronary stent implantation.

Along with the wide use of coronary stenting, adjunctive antiplatelet medications have been improved rapidly in the past decade. The role of ticlopidine plus aspirin in the prevention of subacute thrombosis after coronary stenting had been established. However, failure to prevent restenosis and high incidence of adverse effects remain the limitations of this regimen. Cilostazol, a newly developed antiplatelet agent, has been suggested to reduce restenosis rate after coronary stenting. 8 Previous studies were mainly focused on its safety and effects on prevention of stent thrombosis and restenosis after coronary stent implantation. However, the long-term benefits of cilostazol after stenting have not been demonstrated yet. We conducted a prospective randomized study to evaluate the clinical efficacy of cilostazol for 3 years after coronary stent implantation.